Skip to main
CING

Cingulate (CING) Stock Forecast & Price Target

Cingulate (CING) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Cingulate Inc. operates in a growing market, with total ADHD medication sales in the U.S. increasing approximately 8% annually since 2010, reaching around $18 billion in 2020, which underscores a robust demand for ADHD treatment solutions. The company's proprietary precision timed-release drug delivery platform has shown promise, demonstrated by the positive topline results from the CTx-1301 trial in July 2023, indicating enhanced efficacy compared to placebo. These elements combine to present a favorable outlook for Cingulate's stock, as the company is well-positioned to capitalize on the evolving treatment landscape amidst significant market opportunities.

Bears say

Cingulate Inc reported a net loss of $4.8 million, translating to an earnings per share (EPS) of $(1.09), which fell short of both internal estimates and consensus expectations. Additionally, the company recorded a larger net loss of $7.3 million in a previous period, with an EPS of $(1.35), indicating continued financial strain and operational challenges. Key risks impacting the company's outlook include balance sheet stability, the potential failure of product candidates in clinical trials, regulatory approval hurdles, commercialization difficulties, and broader market factors affecting investor sentiment in the biotech sector.

Cingulate (CING) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Cingulate and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Cingulate (CING) Forecast

Analysts have given Cingulate (CING) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Cingulate (CING) has a Strong Buy consensus rating as of Jan 11, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $31.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $31.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Cingulate (CING)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.